CMPS Fireside Chat @ DB HC Summit 2026: How Psychedelics Could Revolutionize Mental Health

We hosted a fireside chat with the management team of Compass Pathways (CMPS; Not Covered) at our second annual DB Healthcare Summit, featuring CFO Teri Loxam, Chief Commercial Officer Lori Englebert, and Chief Patient Officer Dr. Steve Levine. The discussion focused on the company's ongoing regulatory and commercialization efforts for COMP360 (psilocybin) in treatment-resistant depression (TRD), including NDA progress, launch preparedness, reimbursement strategy, expected treatment utilization, and the evolving competitive landscape within interventional psychiatry. Management continues to guide toward NDA completion in 4Q26 and a potential 1H27 launch, viewing DEA rescheduling as the next key regulatory step and noting that COMP360 would launch into a significantly more developed treatment ecosystem than existed when Spravato was introduced, with roughly 8,000 certified Spravato sites expanding by ~500 per quarter. COMP360 may require a longer monitoring period (~6 hours vs ~2 hours